MX2021011711A - Canagliflozina para el tratamiento de pacientes diabeticos con enfermedad renal cronica. - Google Patents

Canagliflozina para el tratamiento de pacientes diabeticos con enfermedad renal cronica.

Info

Publication number
MX2021011711A
MX2021011711A MX2021011711A MX2021011711A MX2021011711A MX 2021011711 A MX2021011711 A MX 2021011711A MX 2021011711 A MX2021011711 A MX 2021011711A MX 2021011711 A MX2021011711 A MX 2021011711A MX 2021011711 A MX2021011711 A MX 2021011711A
Authority
MX
Mexico
Prior art keywords
canagliflozin
kidney disease
chronic kidney
treatment
diabetic patients
Prior art date
Application number
MX2021011711A
Other languages
English (en)
Spanish (es)
Inventor
Norman R Rosenthal
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2021011711A publication Critical patent/MX2021011711A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021011711A 2019-03-26 2020-03-25 Canagliflozina para el tratamiento de pacientes diabeticos con enfermedad renal cronica. MX2021011711A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962823719P 2019-03-26 2019-03-26
US201962823724P 2019-03-26 2019-03-26
US201962823722P 2019-03-26 2019-03-26
US201962835550P 2019-04-18 2019-04-18
PCT/EP2020/058415 WO2020193652A1 (en) 2019-03-26 2020-03-25 Canagliflozin for the treatment of diabetic patients with chronic kidney disease

Publications (1)

Publication Number Publication Date
MX2021011711A true MX2021011711A (es) 2021-10-22

Family

ID=70050106

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011711A MX2021011711A (es) 2019-03-26 2020-03-25 Canagliflozina para el tratamiento de pacientes diabeticos con enfermedad renal cronica.

Country Status (8)

Country Link
US (1) US20220160739A1 (https=)
EP (1) EP3946367A1 (https=)
JP (2) JP2022526914A (https=)
CN (1) CN113613659A (https=)
CA (1) CA3134786A1 (https=)
MX (1) MX2021011711A (https=)
TW (1) TW202103709A (https=)
WO (1) WO2020193652A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216870A1 (en) * 2021-04-07 2022-10-13 Ur-1 Therapeutics, Inc. Urat1 inhibitor, pharmaceutical compositions and uses thereof
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
AU2015210898A1 (en) * 2014-01-31 2016-07-28 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders

Also Published As

Publication number Publication date
JP2025111453A (ja) 2025-07-30
EP3946367A1 (en) 2022-02-09
WO2020193652A1 (en) 2020-10-01
JP2022526914A (ja) 2022-05-27
CN113613659A (zh) 2021-11-05
US20220160739A1 (en) 2022-05-26
TW202103709A (zh) 2021-02-01
CA3134786A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
CL2024000466A1 (es) Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil
AR047779A1 (es) Composiciones y metodos para tratar diabetes
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CO6150193A2 (es) Terapia tumoral con anticuerpo anti-vegf
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
EA200970944A1 (ru) Применение биполярных транскаротиноидов в качестве предварительного лечения при лечении заболевания периферических сосудов
AR071810A1 (es) Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.
CO2021016870A2 (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa
BR112015004012A2 (pt) combinações de inibidores de sglt 2 e fármacos anti-hipertensivos
EP4684832A3 (en) Potassium-binding agents for treating hypertension and hyperkalemia
PH12020551159A1 (en) Methods of treating subjects having diabetes with chronic kidney disease
EA201792030A1 (ru) Лечение пациентов с сахарным диабетом 2 типа
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
DOP2025000058A (es) Uso de dapaglifozina en la fabricación de un medicamento para el tratamiento de enfermedad renal crónica
CO6592101A2 (es) Metodos para tratar ulceras de pie de diabetico
MX2021011711A (es) Canagliflozina para el tratamiento de pacientes diabeticos con enfermedad renal cronica.
EA201301308A1 (ru) Комбинация для лечения сахарного диабета
ECSP077843A (es) Tratamiento o prevención del prurito
UY39156A (es) Métodos de tratamiento de enfermedad renal crónica con dapagliflozina
BR112013010345A2 (pt) tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
CL2025001515A1 (es) Uso de finerenona para tratar la enfermedad renal crónica en la diabetes mellitus tipo i.
EA202192612A1 (ru) Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек
PE20200889A1 (es) METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa)
AR073585A1 (es) Una proteina rica en cisteina derivada de suero en pacientes que reciben quimioterapia o radioterapia para mejorar la supervivencia de dichos pacientes. uso. metodo